Literature DB >> 29215091

Cancer induction and suppression with transcriptional control and epigenome editing technologies.

Shota Nakade1, Takashi Yamamoto1, Tetsushi Sakuma2.   

Abstract

Cancer epigenetics is one of the most important research subjects in dissecting cancer mechanisms and therapeutic targets because the emergence and malignant transformation of various cancers are caused by unnatural expression of cancer-related genes attributed to their epigenetic errors. The original concept of cancer epigenetics basically stands on the analysis of the epigenetic status in naturally occurring cancer cells; however, the rapidly emerging technology called epigenome editing would change this situation drastically. Epigenome editing, the most promising derivative technology of genome editing, can modify the epigenetic states at the pre-defined genomic locus using the programmable effectors, consisting of various epigenetic factors combined with site-specific DNA-binding domains. This technology can be utilized in a reversible manner; i.e., cancer modeling can be achieved by introducing aberrant epigenetic marks in normal cells, and cancer suppression can be achieved by correcting the epigenetic errors in cancer cells. In this review, we summarize the basics of epigenome editing and cancer epigenetics, followed by the current examples of cancer induction and suppression with the transcriptional control and epigenome editing technologies.

Entities:  

Mesh:

Year:  2017        PMID: 29215091     DOI: 10.1038/s10038-017-0377-8

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  71 in total

Review 1.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  Design of polydactyl zinc-finger proteins for unique addressing within complex genomes.

Authors:  Q Liu; D J Segal; J B Ghiara; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

Review 3.  From profiles to function in epigenomics.

Authors:  Stefan H Stricker; Anna Köferle; Stephan Beck
Journal:  Nat Rev Genet       Date:  2016-11-21       Impact factor: 53.242

4.  TALE-mediated epigenetic suppression of CDKN2A increases replication in human fibroblasts.

Authors:  Diana L Bernstein; John E Le Lay; Elena G Ruano; Klaus H Kaestner
Journal:  J Clin Invest       Date:  2015-04-13       Impact factor: 14.808

5.  Epigenetic reprogramming of cancer cells via targeted DNA methylation.

Authors:  Ashley G Rivenbark; Sabine Stolzenburg; Adriana S Beltran; Xinni Yuan; Marianne G Rots; Brian D Strahl; Pilar Blancafort
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

Review 6.  Zinc finger nucleases as tools to understand and treat human diseases.

Authors:  David Davis; David Stokoe
Journal:  BMC Med       Date:  2010-07-01       Impact factor: 8.775

7.  Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer.

Authors:  S Stolzenburg; A S Beltran; T Swift-Scanlan; A G Rivenbark; R Rashwan; P Blancafort
Journal:  Oncogene       Date:  2015-02-16       Impact factor: 9.867

8.  Repurposing the CRISPR-Cas9 system for targeted DNA methylation.

Authors:  Aleksandar Vojta; Paula Dobrinić; Vanja Tadić; Luka Bočkor; Petra Korać; Boris Julg; Marija Klasić; Vlatka Zoldoš
Journal:  Nucleic Acids Res       Date:  2016-03-11       Impact factor: 16.971

9.  Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences.

Authors:  Sebastian Moran; Carles Arribas; Manel Esteller
Journal:  Epigenomics       Date:  2015-12-17       Impact factor: 4.778

10.  Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system.

Authors:  Benjamin Garcia-Bloj; Colette Moses; Agustin Sgro; Janice Plani-Lam; Mahira Arooj; Ciara Duffy; Shreyas Thiruvengadam; Anabel Sorolla; Rabab Rashwan; Ricardo L Mancera; Andrea Leisewitz; Theresa Swift-Scanlan; Alejandro H Corvalan; Pilar Blancafort
Journal:  Oncotarget       Date:  2016-09-13
View more
  3 in total

Review 1.  Acceleration of cancer science with genome editing and related technologies.

Authors:  Tetsushi Sakuma; Takashi Yamamoto
Journal:  Cancer Sci       Date:  2018-10-31       Impact factor: 6.716

Review 2.  MicroRNAs and Epigenetics Strategies to Reverse Breast Cancer.

Authors:  Mohammad Mijanur Rahman; Andrew C Brane; Trygve O Tollefsbol
Journal:  Cells       Date:  2019-10-08       Impact factor: 6.600

Review 3.  Targeting Epigenetic Modifications in Uveal Melanoma.

Authors:  Pooneh Chokhachi Baradaran; Zuzana Kozovska; Alena Furdova; Bozena Smolkova
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.